Announcements Trials
Browse Landscape

Phase

Phase 4 2Phase 1/2 2

Status

Unknown 1Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 1Genitourinary 1

Conditions

Urologic Diseases 1Nephritis 1Lymphoma, Non-Hodgkin 1Kidney Diseases 1Immune System Diseases 1Glomerulonephritis, IGA 1Glomerulonephritis 1Cardiomyopathies 1Autoimmune Diseases 1

Interventions

Dexamethasone 56Metformin 50Cyclophosphamide 47Saline Solution 39Cytarabine 37Cisplatin 36Zoledronic Acid 34Letrozole 34Carboplatin 33Sodium Chloride 32Bupivacaine 31Docetaxel 30Bevacizumab 30Vincristine 29Methotrexate 29Fluorouracil 28Propofol 27Capecitabine 27Fentanyl 26Doxorubicin 26Rituximab 25Drug Therapy 25Dexmedetomidine 25Prednisone 23Paclitaxel 23Oxaliplatin 21Morphine 21Gemcitabine 21Radiotherapy 19Prednisolone 19

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 4 × Valsartan × Clear all
NCT02765594 2017-09-20

HCQIgAN

Peking Union Medical College Hospital

Phase 4 Unknown
98 enrolled
Genitourinary

Autoimmune Diseases, Glomerulonephritis, Glomerulonephritis, IGA, Immune System Diseases, Kidney Diseases, Nephritis, Urologic Diseases

NCT00162955 2012-05-08

Prevention of CHOP-induced Chronic Cardiotoxicity

Osaka City University

Phase 4 Completed
150 enrolled
Lymphoid

Lymphoma, Non-Hodgkin, Cardiomyopathies

Data powered by HemOnc (CC BY 4.0) Colophon âš¡